Prof Mark Rubin

ProMis Team Member Profile

Mark-RubinProf Mark Rubin, MD, BSc

Institute for Precision Medicine of New York-Presbyterian Hospital and Weill Cornell Medical College

Full research profile




Prof Rubin is Vice Chair of Experimental Pathology at Weill Cornell Medical College, Director of the Institute for Precision Medicine, and Co-Director of the Prostate Cancer Research Program at New York Presbyterian-Weill Cornell. He completed medical school training at Mount Sinai Medical Center, training in anatomic pathology at Georgetown University Medical Center, and a fellowship in anatomic pathology at Johns Hopkins Hospital.

His previous academic appointments include Assistant Professor of Pathology at Columbia University College of Physicians and Surgeons, followed by Associate Professor of Pathology with Tenure at the University of Michigan, then Associate Professor of Pathology at Brigham and Womens Hospital of Harvard Medical School, before being recruited to Weill Cornell Medical College as Professor of Pathology and Laboratory Medicine in 2008.

Prof Rubin’s laboratory is dedicated to prostate cancer biomarker and genomic research and over the past thirteen years has been involved in some of the key prostate cancer biomarker discoveries, including the first expression profiling paper on prostate cancer (Nature 2001), the role of EZH2 in prostate cancer (Nature 2002), the first prostate cancer whole genomes in collaboration with the Broad Institute (Nature 2011, Nature Genetics 2012, Cell 2013). He is the co-discoverer of ETS rearrangements in prostate cancer with Dr. Arul Chinnaiyan (Science 2005). He is the Chair the EDRN Prostate Cancer Collaborative Group and PI of a SU2C Prostate Cancer Foundation Dream Team Award. Prof Rubin is a board certified pathologist and an internationally recognised expert in prostate pathology.

Current funding sources include: United States National Institute of Health, National Cancer Institute and the Early Detection Research Network, Stand Up to Cancer, Prostate Cancer Foundation, Starr Cancer Consortium.